Entrada Therapeutics Stock Gains On Licensing Pact With Vertex For Form Of Neuromuscular Disorder

  • Vertex Pharmaceuticals Incorporated VRTX and Entrada Therapeutics Inc TRDA announced a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV) therapeutics for myotonic dystrophy type 1 (DM1). 
  • The collaboration includes Entrada's program for DM1, ENTR-701, which is in late-stage preclinical development.
  • Under the terms of the agreement, Entrada will receive an upfront payment of $224 million and an equity investment of $26 million. 
  • Also see: Vertex Moves Its Alpha-1 Antitrypsin Deficiency Program Forward.
  • Entrada can receive up to $485 million as milestone payments and tiered royalties on future net sales.
  • The agreement includes a four-year global research collaboration whereby Entrada will continue to advance and receive payments for certain research activities related to ENTR-701 and additional DM1-related research activities. 
  • Vertex will be responsible for the global development, manufacturing, and commercialization of ENTR-701 and any additional programs stemming from Entrada's DM1 research efforts.
  • Price Action: TRDA shares are up 20.4% at $21.33 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!